Stay updated on Pembrolizumab in Relapsed Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Relapsed Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Pembrolizumab in Relapsed Hodgkin Lymphoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe page’s revision tag was updated from v3.6.5 to v3.6.6, reflecting a platform-level update; the study details themselves remain unchanged.SummaryDifference0.1%

- Check20 days agoChange DetectedThe study's list of identifiers now includes a line for '2014 ( U.S. NIH Grant/Contract )', indicating NIH funding for the trial.SummaryDifference0.1%

- Check34 days agoChange DetectedThe page footer now displays Revision: v3.6.5, replacing v3.6.4, indicating a deployed software update to the site rather than a change to the study details.SummaryDifference0.1%

- Check48 days agoChange DetectedRevision tag updated from v3.6.3 to v3.6.4 on the page, indicating a newer build of the site's underlying templates or scripts. This typically reflects minor fixes or updates to the page infrastructure rather than changes to study content.SummaryDifference0.1%

- Check69 days agoChange DetectedThe page's revision tag changed from v3.6.2 to v3.6.3, indicating a new version of the page. This update updates the documentation/version metadata without altering the study content or visible details.SummaryDifference0.1%

- Check77 days agoChange DetectedThe page now displays Revision: v3.6.2, replacing the previous v3.6.0. This indicates a newer page revision.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Relapsed Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Relapsed Hodgkin Lymphoma Clinical Trial page.